Business
Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The company uses computational modeling of cell behavior to treat disease, instead of going after a molecular target, redefining drug discovery through its cell-centric approach.
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
Orna, which began as an academic query at the Massachusetts Institute of Technology (MIT), is a biotechnology company creating fully engineered circular RNA, or O-shaped RNA therapies for the treatment of cancer, autoimmune, and genetic disorders.
Mallon announced his resignation from Ironwood earlier this month to take on a new leadership opportunity and “pursue multiple passions.”
BMS is looking to hire “several hundred employees over the next few years,” all working to ensure the production of both their clinical and commercial cell therapies.
The prosecution alleged that sometime in 2018, Holmes destroyed a database called the Laboratory Information System (LIS), which contained three years’ worth of accuracy and failure rates of Theranos tests.
Life sciences companies across the globe are raking in investment dollars to advance drug programs.
Cancer detection company GRAIL has entered into an agreement with Quest Diagnostics that sees Quest providing phlebotomy services to support GRAIL’s multi-cancer early detection blood test Galleri™.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 23, 2021.
On Monday, the companies announced their checkpoint inhibitor Libtayo (cemiplimab-rwlc) won Food and Drug Administration approval for lung cancer.